Globe News Wire
21 Jul 2026, 06:30 UTC · 6h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Enterome reported a statistically significant correlation between EO2463-induced CD8 T-cell expansion and progression-free survival (PFS) in patients with indolent non-Hodgkin lymphoma (iNHL). — Positive Phase 2 clinical data showing efficacy in extending survival is a primary driver for biotech valuation and regulatory success.
+0.80Enterome believes EO2463 is ready to enter final-stage registrational clinical development and is actively seeking investors and partners. — Moving toward registration increases the likelihood of commercialization, though it signals a need for external capital.
+0.60The FDA granted Orphan Drug Designation (ODD) to EO2463 for the treatment of follicular lymphoma in May 2026. — ODD provides regulatory incentives and market exclusivity, reducing the risk and cost of development.
+0.40Continue reading
6 related stories
Search tags
EO2463 demonstrated an additive effect on complete response rates when used in a triple combination therapy with lenalidomide and rituximab. — Combination efficacy expands the potential market use-cases beyond monotherapy.
+0.40Enterome will present new data on its solid-tumor candidate EO4010 at the ESMO Congress in October 2026. — This provides a near-term catalyst for the company's broader pipeline beyond lymphoma.
+0.20Which stocks this story touches
Positive interim Phase 1/2 data showing EO2463 correlates with progression-free survival in iNHL patients.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
